Bayer, a global leader in the pharmaceutical industry, has announced the acquisition of the remaining 25 percent stake in Bayer Zydus Pharma Private Ltd for ₹282 crore, bringing an end to its 13-year-old joint venture with Zydus Lifesciences Ltd (formerly Cadila Healthcare). This move underscores Bayer’s commitment to strengthening its presence in the Indian pharmaceutical market.
The joint venture, established on January 28, 2011, as a 50:50 partnership, was aimed at the sales and marketing of pharmaceutical products in India. Over the years, the partnership has proven successful, leveraging Zydus’ expertise in marketing and distribution alongside Bayer’s innovative products spanning cardiovascular diseases, diabetes, women’s health, ophthalmology, and oncology.
In 2018, Bayer increased its stake in the joint venture by 25 percent, signaling its confidence in the partnership’s potential for growth. The extension of the partnership in 2021 further demonstrated Bayer’s commitment to the Indian market and its strategic collaboration with Zydus Lifesciences Ltd.
Shweta Rai, Managing Director – India and country division head – South Asia, Bayer Pharmaceuticals Division, emphasized Bayer’s dedication to maintaining its strong presence in India. “We are committed to ensuring our steadfast presence in India as we assume full ownership of Bayer Zydus Pharma,” Rai stated.
The acquisition of the remaining stake in Bayer Zydus Pharma reaffirms Bayer’s confidence in the Indian pharmaceutical market and its long-term growth prospects. With full ownership of the entity, Bayer aims to continue delivering innovative healthcare solutions and meeting the evolving needs of patients across the country.
Bayer‘s strategic move comes at a time when the Indian pharmaceutical industry is witnessing rapid transformation and growth, driven by increasing demand for novel treatments and healthcare solutions. The acquisition further strengthens Bayer’s position as a key player in the Indian pharmaceutical landscape, poised to drive innovation and make a meaningful impact on patient lives.
